CLOs on the Move

Cenegenics

www.cenegenics.com

 
Get a personalized medical team of experts that tests for and treats the earliest signs and avoidable symptoms associated with chronic disease and aging.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cenegenics.com
  • 851, South Rampart Boulevard
    Las Vegas, NV USA 89145
  • Phone: 702.953.1583

Executives

Name Title Contact Details

Similar Companies

Revolution Health Group

Revolution Health Group LLC is a Washington, DC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Harbor Chase Of Auburn Hills

Harbor Chase Of Auburn Hills is a Auburn Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolab

From our humble beginnings in Decatur, GA, in 1955, BioLab today is a leader in providing solutions for recreational and industrial water treatment and home cleaning. Our sales are now in excess of 600 million dollars annually and the stock of our parent

Heathrow Scientific

Heathrow Scientific is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.